Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872156 | 0.83 | FFAR4 (0.45) | RAB9AGAAGPR3MAOBAOC3 | |
| SCHEMBL21617029 | 0.82 | FFAR4 (0.43) | NPC1RAB9AGAAGPR3GMNN | |
| SCHEMBL11030156 | 0.80 | FFAR4 (0.49) | GPR3MAOBAOC3RUNX1FFAR4 | |
| SCHEMBL1905592 | 0.80 | MEN1 (0.46) | RAB9AGPR3MAOBAOC3CYP1A2 | |
| SCHEMBL16952941 | 0.80 | GPR3 (0.42) | RAB9AGPR3MAOBAOC3SLC6A2 | |
| SCHEMBL20526613 | 0.79 | HRH4 (0.43) | NPC1RAB9AGAAGPR3MAOB | |
| SCHEMBL30636513 | 0.79 | GPR3 (0.41) | RAB9AGAAGPR3MAOBAOC3 | |
| SCHEMBL16951952 | 0.79 | CHRM5 (0.42) | GPR3MAOBAOC3LMNACYP3A4 | |
| SCHEMBL16952446 | 0.79 | GPR3 (0.41) | RAB9AGAAGPR3MAOBAOC3 | |
| SCHEMBL16957235 | 0.79 | GPR3 (0.41) | RAB9AGAAGPR3MAOBAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350354-A | Preparation of 10-trifluoro methoxy camptothecine derivative and application thereof in anti-tumor aspect | 兰州大学 | 2025-01-24 | — | — | CN | claimed |
| CN-119350354-A | Preparation of 10-trifluoro methoxy camptothecine derivative and application thereof in anti-tumor aspect | 兰州大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-1620391-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7696205-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-7291615-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1620391-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | NPC1 3367/4885RAB9A 3922/4885GAA 2689/4885 |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | NPC1 1069/4885RAB9A 1938/4885GAA 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.